Horizon Pharma PLC (NASDAQ:HZNP)‘s stock had its “buy” rating reissued by Jefferies Group LLC in a research report issued to clients and investors on Friday. They presently have a $14.00 price objective on the biopharmaceutical company’s stock. Jefferies Group LLC’s price target points to a potential upside of 7.53% from the stock’s current price.

HZNP has been the subject of a number of other research reports. Cantor Fitzgerald started coverage on shares of Horizon Pharma PLC in a research note on Friday, June 16th. They set an “overweight” rating and a $13.00 target price for the company. ValuEngine cut shares of Horizon Pharma PLC from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. BMO Capital Markets restated a “buy” rating and set a $17.00 price target (down from $24.00) on shares of Horizon Pharma PLC in a research report on Tuesday, May 9th. Piper Jaffray Companies lowered their price target on shares of Horizon Pharma PLC from $32.00 to $30.00 and set an “overweight” rating on the stock in a research report on Friday, March 24th. Finally, Stifel Nicolaus restated a “buy” rating and set a $20.00 price target (down from $35.00) on shares of Horizon Pharma PLC in a research report on Tuesday, May 9th. Four equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $20.43.

Horizon Pharma PLC (NASDAQ HZNP) traded down 1.21% on Friday, hitting $13.02. 2,465,526 shares of the company’s stock traded hands. The stock’s market cap is $2.12 billion. Horizon Pharma PLC has a one year low of $9.45 and a one year high of $23.44. The stock has a 50-day moving average of $10.83 and a 200-day moving average of $14.48.

Horizon Pharma PLC (NASDAQ:HZNP) last released its earnings results on Monday, May 8th. The biopharmaceutical company reported $0.21 EPS for the quarter, missing analysts’ consensus estimates of $0.25 by $0.04. The company had revenue of $220.90 million for the quarter, compared to analysts’ expectations of $248.71 million. Horizon Pharma PLC had a positive return on equity of 21.51% and a negative net margin of 21.26%. The firm’s revenue for the quarter was up 7.9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.34 EPS. On average, equities analysts forecast that Horizon Pharma PLC will post $0.84 earnings per share for the current fiscal year.

WARNING: “Horizon Pharma PLC’s (HZNP) “Buy” Rating Reiterated at Jefferies Group LLC” was originally published by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/07/15/horizon-pharma-plcs-hznp-buy-rating-reiterated-at-jefferies-group-llc.html.

In other news, Director Michael G. Grey bought 10,000 shares of the firm’s stock in a transaction on Wednesday, May 10th. The shares were bought at an average cost of $9.48 per share, for a total transaction of $94,800.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 3.20% of the company’s stock.

Several institutional investors have recently modified their holdings of HZNP. BlackRock Inc. raised its position in shares of Horizon Pharma PLC by 68,479.5% in the first quarter. BlackRock Inc. now owns 13,261,212 shares of the biopharmaceutical company’s stock valued at $196,001,000 after buying an additional 13,241,875 shares in the last quarter. Norges Bank bought a new position in shares of Horizon Pharma PLC during the fourth quarter valued at approximately $31,467,000. Highbridge Capital Management LLC raised its position in shares of Horizon Pharma PLC by 128.2% in the first quarter. Highbridge Capital Management LLC now owns 1,545,169 shares of the biopharmaceutical company’s stock valued at $22,837,000 after buying an additional 867,927 shares in the last quarter. Janus Capital Management LLC raised its position in shares of Horizon Pharma PLC by 19.4% in the first quarter. Janus Capital Management LLC now owns 4,409,717 shares of the biopharmaceutical company’s stock valued at $65,173,000 after buying an additional 717,643 shares in the last quarter. Finally, North Tide Capital LLC bought a new position in shares of Horizon Pharma PLC during the first quarter valued at approximately $10,238,000. Hedge funds and other institutional investors own 83.70% of the company’s stock.

About Horizon Pharma PLC

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Analyst Recommendations for Horizon Pharma PLC (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.